Subscribe
shutterstock_1147238582_testing
Testing / Shutterstock.com
7 July 2020BiotechnologyMuireann Bolger

Roche loses appeal to block market entry of rival cancer drug

A  Roche subsidiary will be unable to block  Amgen from producing the cancer drug Mvasi (bevacizumab), the  Court of Appeals for the Federal Circuit has ruled.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Amgen and Roche target Samsung’s Bioepis in patent suit
1 May 2019   Amgen and Roche have filed a joint patent infringement claim against Samsung’s biopharmaceutical company Bioepis.
Americas
AIPPI 2018: Eli Lilly talks IPRs and biosimilar litigation
26 September 2018   The inter partes review process has had a huge impact on biosimilar litigation, but it isn’t truly fulfilling its goal of being an alternative to district court litigation.
Biotechnology
Roche stakes $2bn on UCB Alzheimer’s disease treatment
30 July 2020   Swiss company Roche has partnered with Belgium-based biopharmaceutical company UCB to develop an antibody treatment for people living with Alzheimer’s disease.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Big Pharma
Amgen and Roche target Samsung’s Bioepis in patent suit
1 May 2019   Amgen and Roche have filed a joint patent infringement claim against Samsung’s biopharmaceutical company Bioepis.
Americas
AIPPI 2018: Eli Lilly talks IPRs and biosimilar litigation
26 September 2018   The inter partes review process has had a huge impact on biosimilar litigation, but it isn’t truly fulfilling its goal of being an alternative to district court litigation.
Biotechnology
Roche stakes $2bn on UCB Alzheimer’s disease treatment
30 July 2020   Swiss company Roche has partnered with Belgium-based biopharmaceutical company UCB to develop an antibody treatment for people living with Alzheimer’s disease.

More on this story

Big Pharma
Amgen and Roche target Samsung’s Bioepis in patent suit
1 May 2019   Amgen and Roche have filed a joint patent infringement claim against Samsung’s biopharmaceutical company Bioepis.
Americas
AIPPI 2018: Eli Lilly talks IPRs and biosimilar litigation
26 September 2018   The inter partes review process has had a huge impact on biosimilar litigation, but it isn’t truly fulfilling its goal of being an alternative to district court litigation.
Biotechnology
Roche stakes $2bn on UCB Alzheimer’s disease treatment
30 July 2020   Swiss company Roche has partnered with Belgium-based biopharmaceutical company UCB to develop an antibody treatment for people living with Alzheimer’s disease.

More features

President Trump 2.0: Five major areas to watch
China’s new policies on foreign investment in healthcare and biotech
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug